1xbet 카지노., Ltd.

1xbet 카지노., Ltd. (Otsuka) announces the conclusion of an expanded licensing agreement for hereditary angioedema (HAE) drug candidate donidalorsen (genetic name) with Ionis Pharmaceuticals, Inc. (Ionis) to expand its development and sales area to the Asia-Pacific region, including Japan.

HAE is a rare and potentially life-threaten1xbet 카지노g genetic condition that 1xbet 카지노volves recurrent attacks of severe swell1xbet 카지노g (angioedema) 1xbet 카지노 various parts of the body, 1xbet 카지노clud1xbet 카지노g the hands, feet, genitals, stomach, face and/or throat.

Donidalorsen is an 1xbet 카지노vestigational, RNA-targeted prophylactic medic1xbet 카지노e designed to target prekallikre1xbet 카지노 (PKK), which plays an important role 1xbet 카지노 activat1xbet 카지노g 1xbet 카지노flammatory mediators associated with acute attacks of hereditary angioedema. Ionis recently reported positive results from the Phase 3 OASIS-HAE and OASISplus studies, presented at the 2024 European Academy of Allergy and Cl1xbet 카지노ical Immunology (EAACI) Annual Congress 1xbet 카지노 Valencia, Spa1xbet 카지노 and published 1xbet 카지노The New England of Journal of Medic1xbet 카지노e*.

In December 2023, 1xbet 카지노 and Ionis entereda licens1xbet 카지노g agreementfor 1xbet 카지노 to acquire exclusive rights to commercialize donidalorsen in Europe. 1xbet 카지노 is preparing to submit a Marketing Authorization Application to the European Medicines Agency.

Under the terms of the expanded agreement covering Asia Pacific, 1xbet 카지노 will pay Ionis an upfront payment of USD 20 million, plus milestone payments based on achievement of regulatory and sales targets. Ionis is also eligible to earn royalties on product sales. In addition to Europe, 1xbet 카지노 will apply for regulatory approval and exclusively commercialize the product in Asian-Pacific markets.

1xbet 카지노 has developed drugs globally for rare diseases such as autosomal dominant polycystic kidney disease (ADPKD). Through this collaboration with Ionis, 1xbet 카지노 will strive to deliver donidalorsen to patients across Asia Pacific and in Europe to address the unmet medical needs of patients with HAE.

*Riedl, M.A.et al. Efficacy and Safety of Donidalorsen for Hereditary Angioedema N Engl J Med . 2024 May 31. doi: 10.1056/NEJMoa2402478